On the 2014’s PmLiVE Top Pharma List, Xarelto ranked as 23rd of the top 50 pharmaceutical products by global sales ranking. This ranking translates into big revenue for Bayer and Johnson & Johnson, the makers of the drug, both healthcare giants.
• Reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). There are limited data on the relative effectiveness of XARELTO® (rivaroxaban) and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well controlled. Treatment of deep vein thrombosis (DVT). Treatment of pulmonary embolism (PE). Reduction in the risk of recurrence of DVT and of PE following initial 6 months treatment for DVT and/or PE
• Xarelto is sometimes given to patients who went through total hip or total knee arhtroplasty to prevent pulmonary embolism or deep-vein thrombosis.
• Many hospitals trust that rivaroxaban is a better alternative than low-molecular-weight heparin for thromboprophylaxis in lower limb arthroplasty. But in a study, there were fewer wound complications in low-molecular-weight heparin group compared to rivaroxaban.
There have been a number of adverse effects noted from using Xarelto. These include wound complications and infections. Wound complications associated with Xarelto’ usage for total hip or knee arthroplasty may include; infection, leakage, hematoma, chronic pain and prolonged drainage. Several studies support that these side effects likely happen.
During 2015’s Annual Meeting of the American Academy of Orthopedic Surgeons (AAOS), complications associated with using Xarelto were discussed. A study called Rivaroxaban Use for Thrombosis Prophylaxis is an Independent Risk Factor for Early Periprosthetic Joint Infections was presented; citing the significant higher incidence of deep surgical infection in patients treated with Xarelto. At the same conference, physician Dr. Robert L. Barrack of Washington University School of Medicine presented a review called “Aspirin and Mechanical Compression Sleeves are Best for Most.” to where he cited that prescribing aspirin and mechanical compression to patient should suffice for thromboprophylaxis. Dr. Barrack’s presentation created a debate whether the use of anticoagulant such as Xarelto is necessary of patients after surgery.
Xarelto is a blockbuster and is still a front liner in the blood thinner market with sales exceeding $1 billion. Furthermore, the manufacturers Johnson & Johnson’s and Bayer, announced that they are beginning the studies to find more uses of Xarelto. The manufacturers have already proposed a few extended uses of the drug but the FDA declined these.
Ellen Relkin, Weitz & Luxenberg law firm cited that Xarelto presents 10-fold risk to patients using it. She said at that in a presentation at the American Academy of Orthopedic Surgeons, it was concluded that patients taking Xarelto experienced increased of deep surgical infection.
Now cases against Bayer and Johnson & Johnson’s are flooding across different states in the U.S. Thousands of complaints against both manufacturers are expected to arise soon as more patients come to realize the fatal adverse effects of Xarelto